Palisade Bio Inc (PALI) - Total Assets
Based on the latest financial reports, Palisade Bio Inc (PALI) holds total assets worth $133.31 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PALI net asset quality score to measure how much of total assets are equity-financed.
Palisade Bio Inc - Total Assets Trend (2005–2025)
This chart illustrates how Palisade Bio Inc's total assets have evolved over time, based on quarterly financial data. Check PALI cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Palisade Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Palisade Bio Inc's total assets of $133.31 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.3% |
| Accounts Receivable | $264.00K | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Palisade Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Palisade Bio Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Palisade Bio Inc's current assets represent 99.9% of total assets in 2025, an increase from 92.4% in 2005.
- Cash Position: Cash and equivalents constituted 99.3% of total assets in 2025, up from 92.4% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Palisade Bio Inc Competitors by Total Assets
Key competitors of Palisade Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Palisade Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.71 | 2.84 | 3.82 |
| Quick Ratio | 23.71 | 2.84 | 3.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $127.62 Million | $5.11 Million | $10.88 Million |
Palisade Bio Inc - Advanced Valuation Insights
This section examines the relationship between Palisade Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.64 |
| Latest Market Cap to Assets Ratio | 2.25 |
| Asset Growth Rate (YoY) | 1134.8% |
| Total Assets | $134.34 Million |
| Market Capitalization | $302.38 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Palisade Bio Inc's assets at a significant premium (2.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Palisade Bio Inc's assets grew by 1134.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Palisade Bio Inc (2005–2025)
The table below shows the annual total assets of Palisade Bio Inc from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $134.34 Million | +1134.78% |
| 2024-12-31 | $10.88 Million | -22.57% |
| 2023-12-31 | $14.05 Million | -10.85% |
| 2022-12-31 | $15.76 Million | +25.98% |
| 2021-12-31 | $12.51 Million | +314.44% |
| 2020-12-31 | $3.02 Million | -54.15% |
| 2019-12-31 | $6.58 Million | -14.32% |
| 2018-12-31 | $7.68 Million | -44.65% |
| 2017-12-31 | $13.88 Million | -38.58% |
| 2016-12-31 | $22.60 Million | +51.20% |
| 2015-12-31 | $14.95 Million | -49.91% |
| 2014-12-31 | $29.84 Million | +53.73% |
| 2013-12-31 | $19.41 Million | +121.87% |
| 2012-12-31 | $8.75 Million | +114.14% |
| 2011-12-31 | $4.09 Million | -61.42% |
| 2010-12-31 | $10.59 Million | +252.18% |
| 2009-12-31 | $3.01 Million | -45.01% |
| 2008-12-31 | $5.47 Million | -30.12% |
| 2007-12-31 | $7.83 Million | +304.94% |
| 2006-12-31 | $1.93 Million | +239.15% |
| 2005-12-31 | $569.85K | -- |
About Palisade Bio Inc
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibroste… Read more